BCRABL1 Fusion Protein

• The BCRABL1 fusion protein is an abnormal enzyme resulting from a specific chromosomal translocation.
• It is primarily associated with Chronic Myeloid Leukemia (CML) and some cases of Acute Lymphoblastic Leukemia (ALL).
• This protein acts as a constitutively active tyrosine kinase, driving uncontrolled cell growth and survival.
• Its presence is a key diagnostic marker and a primary therapeutic target for leukemia treatment.
• Targeting BCRABL1 with specific inhibitors has revolutionized the treatment of CML.

What is the BCRABL1 Fusion Protein (BCR-ABL1)?

The BCRABL1 fusion protein (BCR-ABL1) is an abnormal protein created when two genes, BCR (Breakpoint Cluster Region) on chromosome 22 and ABL1 (Abelson murine leukemia viral oncogene homolog 1) on chromosome 9, break and fuse together. This genetic rearrangement is known as the Philadelphia chromosome (Ph chromosome), a reciprocal translocation denoted as t(9;22)(q34;q11). The resulting fusion gene, BCR-ABL1, is transcribed and translated into the BCR-ABL1 fusion protein.

The primary BCRABL1 fusion protein function is that of a constitutively active tyrosine kinase. Unlike its normal ABL1 counterpart, which is tightly regulated, the BCR-ABL1 protein is always “on,” continuously signaling cells to grow and divide without proper control. This unregulated enzymatic activity is a hallmark of its oncogenic potential, leading to a cascade of downstream signaling events that promote cell proliferation, inhibit programmed cell death (apoptosis), and alter cell adhesion.

Role of BCRABL1 in Chronic Myeloid Leukemia Development

The presence of the BCRABL1 fusion protein in leukemia is the defining molecular characteristic of Chronic Myeloid Leukemia (CML), found in over 95% of cases. It is also detected in a subset of patients with Acute Lymphoblastic Leukemia (ALL) and, rarely, in Acute Myeloid Leukemia (AML). In CML, the BCR-ABL1 protein transforms hematopoietic stem cells, leading to an overproduction of myeloid cells in the bone marrow and blood.

The mechanism of how BCRABL1 fusion protein causes cancer involves its continuous activation of several intracellular signaling pathways crucial for cell growth and survival. These pathways include the RAS/MAPK, PI3K/AKT, and JAK/STAT pathways. By keeping these pathways constantly active, BCR-ABL1:

• Promotes uncontrolled proliferation of myeloid cells.
• Inhibits apoptosis, allowing abnormal cells to accumulate.
• Impairs cellular differentiation, leading to the presence of immature cells.
• Reduces cell adhesion, potentially allowing leukemic cells to spread.

This relentless signaling drives the expansion of the leukemic clone, leading to the chronic phase of CML, characterized by an increase in mature and immature granulocytes. Without effective treatment, the disease can progress to an accelerated phase and ultimately to a blastic crisis, which resembles acute leukemia and is much more aggressive. The discovery of the BCR-ABL1 fusion protein revolutionized CML treatment, leading to the development of targeted therapies known as tyrosine kinase inhibitors (TKIs), which specifically block the activity of this abnormal protein. According to the American Cancer Society, CML accounts for approximately 15% of all adult leukemias, with the BCR-ABL1 fusion protein being the primary driver in the vast majority of these cases.